Scinai Immunotherapeutics sets AGM for Dec 22, 2025; files 6-K

Scinai Immunotherapeutics Ltd. scheduled its Annual General Meeting of Shareholders for December 22, 2025 at 11:00 a.m. Israel time at Goldfarb Gross Seligman & Co., One Azrieli Center, Round Tower, Tel Aviv.

Accepted by SEC EDGAR 11/13/2025 - 04:57 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Scinai Immunotherapeutics Ltd. scheduled its Annual General Meeting of Shareholders for December 22, 2025 at 11:00 a.m. Israel time at Goldfarb Gross Seligman & Co., One Azrieli Center, Round Tower, Tel Aviv.

The company furnished a Notice and Proxy Statement as Exhibit 99.1 and a Proxy Card as Exhibit 99.2. This report is incorporated by reference into the company’s Registration Statements on Forms S-8 (File Nos. 333-271293, 333-239344) and F-3 (File Nos. 333-274078, 333-276767).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where is SCNI's 2025 Annual General Meeting?

The meeting is on December 22, 2025 at 11:00 a.m. Israel time at Goldfarb Gross Seligman & Co., One Azrieli Center, Round Tower, Tel Aviv.

What did Scinai Immunotherapeutics furnish with this Form 6-K (SCNI)?

It furnished a Notice and Proxy Statement as Exhibit 99.1 and a Proxy Card as Exhibit 99.2.

Does this 6-K affect SCNI's registration statements?

Yes. It is incorporated by reference into Form S-8 (File Nos. 333-271293, 333-239344) and Form F-3 (File Nos. 333-274078, 333-276767).

What time zone is the SCNI AGM scheduled in?

The meeting time is stated in Israel time.

Who signed the SCNI Form 6-K and when?

It was signed by Amir Reichman, Chief Executive Officer, dated November 13, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of November 2025

Commission File Number: 001-37353

SCINAI IMMUNOTHERAPEUTICS LTD.

(Translation of registrant’s name into English)

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

Jerusalem, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Explanatory Note 

Scinai Immunotherapeutics Ltd. (the “Company”) is scheduling an Annual General Meeting of Shareholders on Thursday, December 22, 2025, at 11:00 a.m. Israel time at the offices of Goldfarb Gross Seligman & Co., One Azrieli Center, Round Tower, Tel Aviv, Israel (the “Meeting”).

The Company hereby furnishes the following documents with respect to the Meeting:

(1) Notice and Proxy Statement with respect to the Meeting, describing the proposals to be voted upon at the Meeting, the procedure for voting in person or by proxy at the Meeting and various other details related to the Meeting; and

(2) Proxy Card whereby holders of the Company’s American Depositary Shares may vote at the meeting without attending in person.

The Notice and Proxy Statement is furnished with this Form 6-K as Exhibit 99.1 and the Proxy Card is furnished with this Form 6-K as Exhibit 99.2

This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344) and Form F-3 (File No. 333-274078 and File No. 333-276767), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit Index

Exhibit No.		Description
99.1		Notice and Proxy Statement of Annual General Meeting of Shareholders.
99.2		Proxy Card.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Scinai Immunotherapeutics Ltd.
Date: November 13, 2025	By:	/s/ Amir Reichman
		Amir Reichman
		Chief Executive Officer

2